Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $30.7 million.

  • Enanta Pharmaceuticals' Accumulated Expenses fell 1088.74% to $30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.7 million, marking a year-over-year decrease of 1088.74%. This contributed to the annual value of $30.7 million for FY2025, which is 1088.74% down from last year.
  • Enanta Pharmaceuticals' Accumulated Expenses amounted to $30.7 million in Q3 2025, which was down 1088.74% from $27.8 million recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Accumulated Expenses ranged from a high of $36.7 million in Q2 2023 and a low of $15.2 million during Q4 2022
  • Over the past 5 years, Enanta Pharmaceuticals' median Accumulated Expenses value was $27.8 million (recorded in 2025), while the average stood at $26.6 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first tumbled by 4295.33% in 2022, then surged by 14079.67% in 2023.
  • Over the past 5 years, Enanta Pharmaceuticals' Accumulated Expenses (Quarter) stood at $26.6 million in 2021, then crashed by 42.95% to $15.2 million in 2022, then skyrocketed by 140.8% to $36.5 million in 2023, then decreased by 10.32% to $32.7 million in 2024, then decreased by 6.21% to $30.7 million in 2025.
  • Its Accumulated Expenses was $30.7 million in Q3 2025, compared to $27.8 million in Q2 2025 and $30.7 million in Q1 2025.